For this purpose, we selected a small cohort of HL and B-cell NHL patients at diagnosis containing a high percentage of CD66b+ cells in the PBMC fraction (≥ 5%) (Figure 4A). This evidence concerns the gene CEACAM8 and Hodgkins lymphoma.